Navigation Links
Independent Study Confirms Superior Properties of ZPC(TM) Enhanced Calcium Composite Bone Grafts

KEELE, England, July 27 /PRNewswire/ -- A recent independent study has confirmed Fortoss Vital(R), developed by the Pioneering Orthobiologics Company, Biocomposites, (, as an effective bone replacement material demonstrating superior bone regenerative properties due to its unique negative zeta potential control (ZPC(TM)).

The research carried out by the hospital and departments of the university of Aachen and the Universities of Munich and Regensburg, Germany, analysed the osteogenic potential of Fortoss Vital for maxillary sinus floor augmentation on a 61 year old female. The samples taken from the graft site at 6 months, showed the negative surface charge of Fortoss Vital had accelerated the bone formation cascade and rapidly produced mature lamellar bone formation with marrow cavities. The bone density at the graft site was shown to be denser than the original bone matrix of the posterior maxillary region. Evidence also confirmed the complete resorption of Fortoss Vital.

Fortoss Vital is a unique, bi-phasic calcium composite bone graft material having a negative surface charge which attracts the key proteins and cells for rapid osteogenesis and bone repair. Fortoss Vital is fully resorbed by osteoclastic processes and replaced by bone.

Biocomposites' Managing Director Stephen Bratt said, "This independent clinical data in a maxillofacial indication, corroborates similar orthopaedic studies confirming that Biocomposites' ZPC technology, with a unique surface chemistry accelerates bone growth.

About the company:

Biocomposites is a privately held, leading developer, manufacturer and distributor of synthetic, tissue regeneration products. Since 1997, the company has developed a broad range of products that addresses the clinical and economic needs of medical specialties in orthopaedics and dentistry. Research, manufacturing, sales and marketing are directed from the company's headquarters in Keele, Staffordshire, UK. Biocomposites also has two subsidiary companies, based in Shanghai, P.R.China and Wilmington, North Carolina, USA.

Fortoss Vital(R) and Biocomposites(R) The Next Regeneration(TM) are registered trademarks of Biocomposites Ltd.


Smeets et al. " A new biphasic osteoinductive calcium composite material with a negative Zeta potential for bone augmentation." Head & face Medicine 2009, 5:13 doi:10.1186/1746-160X-5-13.

SOURCE Biocomposites Ltd
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BioNeutrals Ygiene(TM) Hospital Grade Achieves a 100% Total Kill (Pass) Against the Life Threatening Clostridium Difficile (C.diff) Spores in Independent EPA Required Protocol Testing.
2. BioNeutrals Ygiene(TM) Hospital Grade Achieves World Class Independent Test Results in Killing Life Threatening Spores/Organisms
3. BioNeutrals Ygiene(TM) Hospital Grade Antimicrobial Demonstrates a 99.9997% Kill Rate Against Clostridium Difficile Spores (C.diff) in Independent Lab Pre-testing Phase
4. Independent U.S. Study Confirms Veritides Ceeker(TM) Handheld Device Detects Anthrax With Outstanding Accuracy and Reliability
5. Independent Data Monitoring Committee Supports Continuation of Picoplatin Phase 3 SPEAR Registration Trial in Small Cell Lung Cancer
6. 3SBio Inc. Announces Appointment of Ernst & Young Hua Ming as Independent Auditor
7. Concerned Shareholders of Biovail Announce - Independent Nominees for Election to Biovail Board of Directors - A Focused Commitment to Governance at Biovail
8. Spherix Recruiting New Independent Director to Regain NASDAQ Compliance
9. Independent Study Corroborates Pranas Strategy to Treat Alzheimers Disease Patients.
10. Virginia Tech engineers investigate energy independent monitoring system for bridges
11. Immtech Announces Appointment of Virchow Krause as Independent Registered Public Accounting Firm
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the leading software as ... Clinical Reach Virtual Patient Encounter CONSULT module which enables both audio and video ... trial team. , Using the CONSULT module, patients and physicians can schedule a face ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... the funding of a Sponsored Research Agreement with ... tumor cells (CTCs) from cancer patients.  The funding ... CTC levels correlate with clinical outcomes in cancer ... data will then be employed to support the ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader ... “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, ... providing practical tips, tools, and strategies for clinical researchers. , “The landscape of ...
Breaking Biology Technology:
(Date:6/15/2016)... 15, 2016 Transparency Market ... Recognition Market by Application Market - Global Industry Analysis Size ... to the report, the  global gesture recognition market ... and is estimated to grow at a CAGR ... 2024.  Increasing application of gesture recognition ...
(Date:6/3/2016)... 3, 2016 Das ... Nepal hat ein 44 ... geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, ... Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte ... Januar teilgenommen, aber Decatur wurde als konformste ...
(Date:6/1/2016)... , June 1, 2016 ... in Election Administration and Criminal Identification to Boost Global ... a recently released TechSci Research report, " Global Biometrics ... Region, Competition Forecast and Opportunities, 2011 - 2021", the ... billion by 2021, on account of growing security concerns ...
Breaking Biology News(10 mins):